From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
Figure 2. Detection of EGFR mutations in liquid biopsy samples with 20% heparin-plasma. MDX092 (red) enabled reliable detection of low- level E19del mutations down to 10 copies, even in the presence of PCR inhibitors. In the same conditions, other commercially available mixes (blue, green) showed limited or no amplification. This highlights the importance of inhibitor-tolerant reagent systems for detecting rare variants in plasma-based assays.
• Ambient-stable for cost-efficient, scalable, and accessible testing: Eliminates cold chain, simplifies logistics, and supports assay deploy- ment in any setting. • Workflow-Ready Master Mixes: Meridian’s qPCR and RT-qPCR master mixes are pre-opti- mized for multiplexing, fast cycling and automa- tion, offering consistency across platforms and simplifying assay development.
biopsy samples, assay performance was assessed using a model for EGFR mutation detection. Key benefits include: • Reliable with low-input DNA: High processivity enables efficient amplification from fragmented or limited samples. • Performs in challenging sample types: Enhanced inhibitor tolerance for robust perfor- mance across diverse sample types
GENengnews.com | 27
Powered by FlippingBook